In a mouse model of acute ischemic stroke, researchers showed that inhibiting the aggregation of GAPDH, either genetically or with a novel peptide, significantly reduced brain damage and improved neurological function. The findings highlight GAPDH aggregation as a promising therapeutic target for stroke intervention.